{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:18:33Z","timestamp":1781763513211,"version":"3.54.5"},"reference-count":101,"publisher":"Elsevier BV","issue":"49","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vaccine.2022.10.047","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T00:23:11Z","timestamp":1667089391000},"page":"7022-7031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development"],"prefix":"10.1016","volume":"40","author":[{"given":"Lilan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.10.047_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ehb.2021.101039","article-title":"The impact of past pandemics on economic and gender inequalities","volume":"43","author":"Brzezinski","year":"2021","journal-title":"Econ Hum Biol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0010","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","article-title":"Antivirals with common targets against highly pathogenic viruses","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2022.10.047_b0015","unstructured":"Simonsen KA, Snowden J. Smallpox. 2021."},{"key":"10.1016\/j.vaccine.2022.10.047_b0020","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14760584.2020.1791093","article-title":"Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication","volume":"19","author":"Thompson","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.10.047_b0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.10.047_b0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26.COV2.S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.10.047_b0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"713\u2013721","key":"10.1016\/j.vaccine.2022.10.047_b0040","first-page":"e719","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2022.10.047_b0045","unstructured":"Poxviridae Moss B. The Viruses and Their Replication. In Fields\u2019Virology, 5th ed.; Knipe DM, Howley PM, Eds.; Wolters Kluwer Health\/Lippincott Williams & Wilkins: Philadelphia, PA, USA. 2007:pp.2906-2945."},{"key":"10.1016\/j.vaccine.2022.10.047_b0050","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1016\/j.vaccine.2022.08.054","article-title":"Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibody","volume":"40","author":"Cao","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.047_b0055","doi-asserted-by":"crossref","unstructured":"Americo JL, Cotter CA, Earl PL, Liu R, Moss B. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection. Proc Natl Acad Sci USA 2022,119:e2202069119.","DOI":"10.1073\/pnas.2202069119"},{"key":"10.1016\/j.vaccine.2022.10.047_b0060","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1128\/JVI.03247-12","article-title":"Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys","volume":"87","author":"Sun","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0065","doi-asserted-by":"crossref","first-page":"e68115","DOI":"10.1371\/journal.pone.0068115","article-title":"Deletion of C7L and K1L genes leads to significantly decreased virulence of recombinant vaccinia virus TianTan","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.10.047_b0070","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/QAD.0000000000000595","article-title":"HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection","volume":"29","author":"Liu","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2022.10.047_b0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.all.0000136758.66442.28","article-title":"Smallpox, vaccination and adverse reactions to smallpox vaccine","volume":"4","author":"Wollenberg","year":"2004","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0080","first-page":"471","article-title":"Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy","volume":"1","author":"Hwang","year":"1999","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.vaccine.2022.10.047_b0085","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1086\/432584","article-title":"Generalized vaccinia, progressive vaccinia, and eczema vaccinatum are rare following smallpox (vaccinia) vaccination: United States surveillance, 2003","volume":"41","author":"Vellozzi","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.047_b0090","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/02648725.2018.1471643","article-title":"Vaccinia-based vaccines to biothreat and emerging viruses","volume":"34","author":"Nagata","year":"2018","journal-title":"Biotechnol Genet Eng Rev"},{"key":"10.1016\/j.vaccine.2022.10.047_b0095","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1080\/21645515.2020.1840887","article-title":"Vaccinia virus-based vector against infectious diseases and tumors","volume":"17","author":"Zhang","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.10.047_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8110491","article-title":"Design and engineering of deimmunized vaccinia viral vectors","author":"Song","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.vaccine.2022.10.047_b0105","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0264-410X(00)00191-2","article-title":"Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus\u2013poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans","volume":"19","author":"Kanesa-thasan","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.047_b0110","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.10.047_b0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.coviro.2020.10.006","article-title":"Tools for the targeted genetic modification of poxvirus genomes","volume":"44","author":"Matia","year":"2020","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0120","doi-asserted-by":"crossref","unstructured":"Wyatt LS, Earl PL, Moss B. Generation of Recombinant Vaccinia viruses. Curr Protoc Microbiol 2015,39:14A 14 11-14A 14 18.","DOI":"10.1002\/9780471729259.mc14a04s39"},{"key":"10.1016\/j.vaccine.2022.10.047_b0125","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1016\/j.vaccine.2013.07.057","article-title":"Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants","volume":"31","author":"Melamed","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.047_b0130","doi-asserted-by":"crossref","first-page":"e24296","DOI":"10.1371\/journal.pone.0024296","article-title":"Unpolarized release of vaccinia virus and HIV antigen by colchicine treatment enhances intranasal HIV antigen expression and mucosal humoral responses","volume":"6","author":"Zhang","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.10.047_b0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.antiviral.2018.03.004","article-title":"Improved immune response against HIV-1 Env antigen by enhancing EEV production via a K151E mutation in the A34R gene of replication-competent vaccinia virus Tiantan","volume":"153","author":"Yu","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2022.10.047_b0140","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.virusres.2018.06.017","article-title":"Construction of an attenuated Tian Tan vaccinia virus strain by deletion of TA35R and TJ2R genes","volume":"256","author":"Li","year":"2018","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2022.10.047_b0145","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3389\/fcimb.2017.00462","article-title":"Generation of an attenuated tiantan vaccinia virus strain by deletion of multiple genes","volume":"7","author":"Li","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-61779-876-4_3","article-title":"Genetic manipulation of poxviruses using bacterial artificial chromosome recombineering","volume":"890","author":"Cottingham","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/v3030217","article-title":"An efficient method for generating poxvirus recombinants in the absence of selection","volume":"3","author":"Rice","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2022.10.047_b0160","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nmeth734","article-title":"Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage lambda-based recombination","volume":"2","author":"Domi","year":"2005","journal-title":"Nat Methods"},{"key":"10.1016\/j.vaccine.2022.10.047_b0165","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.1128\/JVI.00339-15","article-title":"Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system","volume":"89","author":"Yuan","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-4939-9593-6_6","article-title":"Vaccinia virus genome editing using CRISPR","volume":"2023","author":"Di Gioia","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0175","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1038\/s41598-018-24820-2","article-title":"Effects of pre-existing orthopoxvirus-specific immunity on the performance of modified vaccinia virus ankara-based influenza vaccines","volume":"8","author":"Altenburg","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.10.047_b0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1099\/vir.0.82216-0","article-title":"Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization","volume":"88","author":"Naito","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0185","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1016\/j.vaccine.2015.07.010","article-title":"Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity","volume":"33","author":"Korioth-Schmitz","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.047_b0190","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.humimm.2012.07.328","article-title":"Impact of infection or vaccination on pre-existing serological memory","volume":"73","author":"Amanna","year":"2012","journal-title":"Hum Immunol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0195","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/gt.2010.104","article-title":"The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host","volume":"17","author":"Guo","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2022.10.047_b0200","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1016\/j.vaccine.2009.05.018","article-title":"Recombinant modified vaccinia ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity","volume":"27","author":"Gudmundsdotter","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.047_b0205","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0140-6736(91)91636-9","article-title":"Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein","volume":"337","author":"Cooney","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.10.047_b0210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2307\/1592516","article-title":"Failure of a recombinant fowl poxvirus vaccine containing an avian influenza hemagglutinin gene to provide consistent protection against influenza in chickens preimmunized with a fowl pox vaccine","volume":"44","author":"Swayne","year":"2000","journal-title":"Avian Dis"},{"key":"10.1016\/j.vaccine.2022.10.047_b0215","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/s41467-018-03662-6","article-title":"A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses","volume":"9","author":"Prow","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2022.10.047_b0220","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.4049\/jimmunol.1000751","article-title":"Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA\/MVA vaccine","volume":"185","author":"Kannanganat","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0225","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1128\/jvi.62.5.1530-1534.1988","article-title":"Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination","volume":"62","author":"Rooney","year":"1988","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0230","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1016\/j.vaccine.2019.04.070","article-title":"Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice","volume":"37","author":"Xie","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.047_b0235","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1089\/vim.2019.0164","article-title":"Administration with vaccinia virus encoding canine parvovirus 2 vp2 elicits systemic immune responses in mice and dogs","volume":"33","author":"Zhao","year":"2020","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0240","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/S0264-410X(00)00121-3","article-title":"Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge","volume":"18","author":"Men","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.047_b0245","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","article-title":"The continued threat of emerging flaviviruses","volume":"5","author":"Pierson","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0250","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-019-08641-z","article-title":"Japanese encephalitis virus neuropenetrance is driven by mast cell chymase","volume":"10","author":"Hsieh","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2022.10.047_b0255","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/gcb.15384","article-title":"Warming temperatures could expose more than 1.3 billion new people to Zika virus risk by 2050","volume":"27","author":"Ryan","year":"2021","journal-title":"Glob Chang Biol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16245114","article-title":"Climate change, health and mosquito-borne diseases: trends and implications to the pacific region","author":"Filho","year":"2019","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.vaccine.2022.10.047_b0265","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(19)30803-7","article-title":"Disease X and other unknowns","volume":"393","author":"Honigsbaum","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.10.047_b0270","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1473-3099(20)30123-7","article-title":"Disease X: accelerating the development of medical countermeasures for the next pandemic","volume":"20","author":"Simpson","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.047_b0275","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/jvi.64.6.2788-2795.1990","article-title":"Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus","volume":"64","author":"Yasuda","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0280","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/0042-6822(92)91233-K","article-title":"A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine","volume":"190","author":"Konishi","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2022.10.047_b0285","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0042-6822(91)90788-D","article-title":"Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus","volume":"185","author":"Konishi","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2022.10.047_b0290","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0042-6822(91)90034-9","article-title":"Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection","volume":"180","author":"Mason","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2022.10.047_b0295","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1016\/j.vaccine.2016.10.058","article-title":"A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis","volume":"34","author":"Quinan","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.047_b0300","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4110\/in.2011.11.5.268","article-title":"Distinct humoral and cellular immunity induced by alternating prime-boost vaccination using plasmid DNA and live viral vector vaccines expressing the e protein of dengue virus type 2","volume":"11","author":"George","year":"2011","journal-title":"Immune Netw"},{"key":"10.1016\/j.vaccine.2022.10.047_b0305","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0264-410X(94)90206-2","article-title":"Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice","volume":"12","author":"Fonseca","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.047_b0310","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1128\/jvi.64.9.4356-4363.1990","article-title":"Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis","volume":"64","author":"Falgout","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0315","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1128\/jvi.63.6.2853-2856.1989","article-title":"Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis","volume":"63","author":"Bray","year":"1989","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0320","doi-asserted-by":"crossref","unstructured":"Perez P, QM M, Lazaro-Frias A, Jimenez de Oya N, Blazquez AB, Escribano-Romero E, et al. A Vaccine Based on a Modified Vaccinia virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice. Sci Rep 2018,8:17385.","DOI":"10.1038\/s41598-018-35724-6"},{"key":"10.1016\/j.vaccine.2022.10.047_b0325","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.vaccine.2019.02.063","article-title":"Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates","volume":"37","author":"Zhan","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.047_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens8040216","article-title":"Assessment of immunogenicity and efficacy of a zika vaccine using modified vaccinia ankara virus as carriers","author":"Lopez-Camacho","year":"2019","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2022.10.047_b0335","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41541-020-0191-8","article-title":"The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates","volume":"5","author":"Prow","year":"2020","journal-title":"NPJ Vac"},{"key":"10.1016\/j.vaccine.2022.10.047_b0340","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1038\/s41598-021-85951-7","article-title":"Single dose of a replication-defective vaccinia virus expressing Zika virus-like particles is protective in mice","volume":"11","author":"Jasperse","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.10.047_b0345","doi-asserted-by":"crossref","first-page":"14769","DOI":"10.1038\/s41598-017-15039-8","article-title":"A Zika vaccine targeting NS1 protein protects immunocompetent adult mice in a lethal challenge model","volume":"7","author":"Brault","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.10.047_b0350","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.vaccine.2016.02.042","article-title":"Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens","volume":"34","author":"Volz","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.10.047_b0355","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4161\/hv.26902","article-title":"Japanese encephalitis: the virus and vaccines","volume":"10","author":"Yun","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.10.047_b0360","first-page":"1","author":"Japanese","year":"2020","journal-title":"Curr Treat Options Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.047_b0365","unstructured":"Schaefer TJ, Panda PK, Wolford RW. Dengue Fever. 2021."},{"key":"10.1016\/j.vaccine.2022.10.047_b0370","doi-asserted-by":"crossref","DOI":"10.1139\/cjm-2020-0572","article-title":"Dengue virus: epidemiology, biology and disease aetiology","author":"Roy","year":"2021","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0375","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2020.572681","article-title":"Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine","volume":"10","author":"Shukla","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0380","first-page":"1","article-title":"Dengue vaccine: an update","author":"Huang","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.vaccine.2022.10.047_b0385","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3389\/fimmu.2019.02125","article-title":"Human T cell response to dengue virus infection","volume":"10","author":"Tian","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0390","doi-asserted-by":"crossref","unstructured":"Yan Y, Hu K, Fu M, Deng X, Luo S, Tong L, et al. CCL19 and CCL28 assist herpes simplex virus 2 glycoprotein D to induce protective systemic immunity against genital viral challenge. mSphere 2021,6.","DOI":"10.1128\/mSphere.00058-21"},{"key":"10.1016\/j.vaccine.2022.10.047_b0395","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00284-020-02284-w","article-title":"Current understanding of the pathogenesis of dengue virus infection","volume":"78","author":"Bhatt","year":"2021","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0400","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.biotechadv.2017.09.004","article-title":"Zika virus structural biology and progress in vaccine development","volume":"36","author":"Lin","year":"2018","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2022.10.047_b0405","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-med-040717-051127","article-title":"Zika virus vaccine development: progress in the face of new challenges","volume":"70","author":"Diamond","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2022.10.047_b0410","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192152","article-title":"Japanese encephalitis virus-primed CD8+ T cells prevent antibody-dependent enhancement of Zika virus pathogenesis","volume":"217","author":"Chen","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2022.10.047_b0415","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4269\/ajtmh.16-0323","article-title":"Zika virus and chikungunya virus coinfections: a series of three cases from a single center in ecuador","volume":"95","author":"Zambrano","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.10.047_b0420","unstructured":"Clark MB, Schaefer TJ. West Nile Virus. 2021."},{"key":"10.1016\/j.vaccine.2022.10.047_b0425","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9121073","article-title":"Animal and Human Vaccines against West Nile Virus","author":"Saiz","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2022.10.047_b0430","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1073\/pnas.0711874105","article-title":"Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes","volume":"105","author":"McMurtrey","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2022.10.047_b0435","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: current perspectives","volume":"154\u2013155","author":"Samaridou","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2022.10.047_b0440","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of virus-like particles for vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"N Biotechnol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0445","unstructured":"Damon. Poxviridae. In Fields\u2019Virology, 5th ed.; Knipe, D.M., Howley, P.M., Eds.; Wolters Kluwer Health\/Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007, pp. 2948-2975."},{"key":"10.1016\/j.vaccine.2022.10.047_b0450","doi-asserted-by":"crossref","first-page":"e55488","DOI":"10.1371\/journal.pone.0055488","article-title":"Transmissibility of the monkeypox virus clades via respiratory transmission: investigation using the prairie dog-monkeypox virus challenge system","volume":"8","author":"Hutson","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.10.047_b0455","doi-asserted-by":"crossref","first-page":"e28295","DOI":"10.1371\/journal.pone.0028295","article-title":"Monkeypox disease transmission in an experimental setting: prairie dog animal model","volume":"6","author":"Hutson","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.10.047_b0460","article-title":"The outbreak of monkeypox 2022: an overview","volume":"79","author":"Hraib","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.vaccine.2022.10.047_b0465","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13578-021-00610-8","article-title":"Why do poxviruses still matter?","volume":"11","author":"Yang","year":"2021","journal-title":"Cell Biosci"},{"key":"10.1016\/j.vaccine.2022.10.047_b0470","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00475-19","article-title":"Optimized Mucosal Modified Vaccinia virus Ankara Prime\/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen","volume":"93","author":"Jones","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0475","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1073\/pnas.96.8.4512","article-title":"Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity","volume":"96","author":"Belyakov","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2022.10.047_b0480","article-title":"One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2022.10.047_b0485","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14760584.2018.1522255","article-title":"Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines","volume":"17","author":"Prow","year":"2018","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2022.10.047_b0490","article-title":"A Monovalent and trivalent MVA-based vaccine completely protects mice against lethal Venezuelan, Western, and Eastern equine encephalitis virus aerosol challenge","volume":"11","author":"Henning","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0495","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/infdis\/jiaa460","article-title":"Broad antibody and cellular immune response from a phase 2 clinical trial with a novel multivalent poxvirus-based respiratory syncytial virus vaccine","volume":"223","author":"Jordan","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.10.047_b0500","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12866-021-02121-5","article-title":"Construction of a bivalent vaccine against anthrax and smallpox using the attenuated vaccinia virus KVAC103","volume":"21","author":"Park","year":"2021","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2022.10.047_b0505","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1128\/CVI.00006-10","article-title":"Highly persistent and effective prime\/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant","volume":"17","author":"Kolibab","year":"2010","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22013111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:19:29Z","timestamp":1759403969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22013111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":101,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0264410X22013111"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in vaccinia virus-based vaccine vectors, with applications in flavivirus vaccine development","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}